Barr Pharmaceuticals, Inc.

Oral contraceptives maker reports earnings of $2.03 per share

Published in Physician Law Weekly, October 5th, 2005

Barr Pharmaceuticals, Inc., (BRL) reported net earnings of $215.0 million, or $2.03 per fully diluted share, on revenues of $1.05 billion for the fiscal year ended June 30, 2005.

The current year results compare with prior year net earnings of $123.1 million, or $1.15 per fully diluted share, on total revenues of $1.31 billion. Adjusted net earnings for fiscal 2005 were $254.3 million, or $2.40 per fully diluted share excluding a charge of $0.37 per fully diluted share related to a potential litigation settlement and product acquisition of Organon's Mircette oral contraceptive product.

Adjusted net earnings for the fiscal year ended June 30, 2004,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2005-10-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry